12-19 | Cases of cholera may have declined in Yemen, but the ongoing war and blockade are now creating a new threat to public health, as a suspected diphtheria outbreak takes hold. By 4 December, 318 suspected cases of diphtheria and 28 deaths had been reported in 15 of Yemen’s 20 governorates. Half the suspected cases are children between the ages of 5 and 14, and nearly 95% of deaths are children under 15.
MSF challenges Gilead’s patent application for hepatitis C combination treatment in China, to bring down prices
12-18 | Gilead recently launched one of these drugs for $100/pill in China Médecins Sans Frontières (MSF) has filed a legal patent challenge in China against US pharmaceutical corporation Gilead’s patent application for the combination of two crucial oral hepatitis C medicines, sofosbuvir and velpatasvir. This combination is the first direct-acting antiviral (DAA) treatment to be registered for use against all genotypes* of the disease.
10-31 | Dramatic price drops should allow countries to provide treatment for millions of people On the eve of the World Hepatitis Summit in Sao Paolo, the international medical humanitarian organization Médecins Sans Frontières (MSF) today announced that it had secured deals for generic hepatitis C medicines for as low as US$1.40 per day, or $120 per 12-week treatment course for the two key medicines sofosbuvir and daclatasvir. In the US, pharmaceutical corporation Gilead launched sofosbuvir at $1,000 per pil
6-9 | As fighting intensifies for control of the Syrian city of Raqqa, people must decide whether to remain in the city and surrounding villages under heavy bombardment, or leave the area by crossing active frontlines and minefields, says Médecins Sans Frontières/ Doctors Without Borders (MSF). “Parents have to make an impossible decision,” says MSF emergency coordinator Puk Leenders.
5-5 | Manila, Philippines is set to host the 18th round of the multilateral trade deal - the Regional Comprehensive Economic Partnership (RCEP) that encompasses 50% of the global population. With the Philippines holding the chairmanship of ASEAN for 2017, it can be an opportune time for Philippines to take the lead in ensuring that market gains will not trump the right of millions of people to access affordable medicines.